Graphite Bio Inc
NASDAQ:LENZ
Graphite Bio Inc
Graphite Bio, Inc. operates as a clinical-stage gene editing company. The company is headquartered in South San Francisco, California and currently employs 120 full-time employees. The company went IPO on 2021-06-25. The firm has a gene editing platform that is designed to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its research program, GPH102 for the treatment of beta-thalassemia, leverages its gene replacement platform technology by replacing one or both copies of the mutated beta-globin (HBB) gene through HDR to restore HgbA expression to levels. GPH201 is an investigational treatment for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene (IL2RG) prevent normal immune system function. GPH301 is for the treatment of Gaucher disease. Its pipeline program also includes therapeutic protein production and non-genotoxic conditioning (NGTC).
Graphite Bio, Inc. operates as a clinical-stage gene editing company. The company is headquartered in South San Francisco, California and currently employs 120 full-time employees. The company went IPO on 2021-06-25. The firm has a gene editing platform that is designed to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its research program, GPH102 for the treatment of beta-thalassemia, leverages its gene replacement platform technology by replacing one or both copies of the mutated beta-globin (HBB) gene through HDR to restore HgbA expression to levels. GPH201 is an investigational treatment for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene (IL2RG) prevent normal immune system function. GPH301 is for the treatment of Gaucher disease. Its pipeline program also includes therapeutic protein production and non-genotoxic conditioning (NGTC).
FDA Approval: LENZ received early FDA approval for VIZZ in July, ahead of the scheduled PDUFA date.
Product Launch: VIZZ, the first aceclidine-based eye drop for presbyopia, launched commercially in the US in early October.
Strong Early Adoption: Over 2,500 doctors prescribed VIZZ within the first month, with 40% writing multiple prescriptions and more than 5,000 paid prescriptions filled in October.
Awareness & Confidence: Eye care professional awareness of VIZZ reached 90% just weeks after launch, supported by robust sampling and marketing.
Financial Strength: LENZ raised $123 million in October, ending Q3 with $324 million in cash and equivalents, supporting its launch strategy and projected cash needs.
Operating Expenses: SG&A more than doubled sequentially to $27.6 million in Q3, reflecting commercial ramp; R&D expenses decreased as development needs waned.
DTC Campaign: A direct-to-consumer campaign featuring Sarah Jessica Parker as spokesperson is set to launch in Q1 2026.
Market Feedback: Early real-world feedback is positive, with rapid vision improvement and minimal side effects; pricing is not seen as a barrier.
